Plasma ADMA associates with all-cause mortality in renal transplant recipients

Amino Acids

Volumn 47, Issue 9, 2015, Pages 1941-1949

  Frenay, Anne Roos S ^a   Van Den Berg, Else ^a   De Borst, Martin H ^a   Beckmann, Bibiana ^b   Tsikas, Dimitrios ^b   Feelisch, Martin ^c   Navis, Gerjan ^a   Bakker, Stephan J L ^a   Van Goor, Harry ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Asymmetric dimethylarginine; Kidney; Survival; Transplantation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PARATHYROID HORMONE; ARGININE; N,N-DIMETHYLARGININE;

ADULT; ARTICLE; CLINICAL EVALUATION; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; AGED; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; GRAFT REJECTION; KIDNEY TRANSPLANTATION; METABOLISM; MIDDLE AGED; VASCULAR ENDOTHELIUM;

ADULT; AGED; ARGININE; DISEASE-FREE SURVIVAL; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SURVIVAL RATE;

EID: 84940462909     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-015-2023-0     Document Type: Article

References (36)

1. Abedini S, Meinitzer A, Holme I et al (2010) Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 77:44-50
2. Albrecht EW, Stegeman CA, Tiebosch AT et al (2002) Expression of inducible and endothelial nitric oxide synthases, formation of peroxynitrite and reactive oxygen species in human chronic renal transplant failure. Am J Transplant 2:448-453
3. Baia LC, Van den Berg E, Vervloet MG et al (2014) Fish and omega-3 fatty acid intake in relation to circulating fibroblast growth factor 23 levels in renal transplant recipients. Nutr Metab Cardiovasc Dis 24:1310-1316
4. Boger RH, Bode-Boger SM, Szuba A et al (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98:1842-1847
5. Can A, Bekpinar S, Gurdol F et al (2011) Dimethylarginines in patients with type 2 diabetes mellitus: relation with the glycaemic control. Diabetes Res Clin Pract 94:e61-e64
6. Cooke JP (2000) Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20:2032-2037
7. Davids M, Teerlink T (2013) Plasma concentration of arginine and asymmetric dimethylarginine do not reflect their intracellular concentrations in peripheral blood mononuclear cells. Metabolism 62:1455-1461
8. Davids M, van Hell AJ, Visser M et al (2012) Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine. Am J Physiol Heart Circ Physiol 302:1762-1770
9. Dubois D, Dubois EF (1989) A formula to estimate the approxiamte surface area if height and wight be known 1916. Nutrition 5:303-311
10. Duckelmann C, Mittermayer F, Haider DG et al (2007) Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 27:2037-2042
11. Faraci FM, Brian JE Jr, Heistad DD (1995) Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 269:H1522-H1527
12. Fliser D, Kronenberg F, Kielstein JT et al (2005) Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 16:2456-2461
13. Gardiner SM, Kemp PA, Bennett T et al (1993) Regional and cardiac haemodynamic effects of NG, NG, dimethyl-l-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol 110:1457-1464
14. Hanai K, Babazono T, Nyumura I et al (2009) Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 24:1884-1888
15. Hariharan S, McBride MA, Cherikh WS et al (2002) Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 62:311-318
16. Huang PL, Huang Z, Mashimo H et al (1995) Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377:239-242
17. Kielstein JT, Impraim B, Simmel S et al (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109:172-177
18. Leiper JM (2005) The DDAH-ADMA-NOS pathway. Ther Drug Monit 27:744-746
19. Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604-612
20. Lu TM, Chung MY, Lin CC et al (2011) Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol 6:1566-1572
21. Malyszko J, Koc-Zorawska E, Matuszkiewicz-Rowinska J, Malyszko J (2014) FGF23 and Klotho in relation to markers of endothelial dysfunction in kidney transplant recipients. Transplant Proc 46:2647-2650
22. Meinitzer A, Kielstein JT, Pilz S et al (2011) Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk an Cardiovascular Health study. Clin Chem 57:112-121
23. Mihout F, Shweke N, Bige N et al (2011) Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-beta1 synthesis. J Pathol 223:37-45
24. Nakayama T, Sato W, Kosugi T et al (2009) Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse. Am J Physiol Renal Physiol 296:F317-F327
25. Ravani P, Tripepi G, Malberti F et al (2005) Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 16:2449-2455
26. Shi B, Ni Z, Zhou W et al (2010) Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur J Intern Med 21:444-448
27. Surdacki A, Nowicki M, Sandmann J et al (1999) Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33:652-658
28. Tripepi G, Kollerits B, Leonardis D et al (2015) Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD. J Am Soc Nephrol 26:935-944
29. Tsikas D, Schubert B, Gutzki FM et al (2003) Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-pentafluoropropionyl) derivative. J Chromatogr B Analyt Technol Biomed Life Sci 798:87-99
30. van den Berg E, Engberink MF, Brink EJ et al (2012a) Dietary acid load and metabolic acidosis in renal transplant recipients. Clin J Am Soc Nephrol 7:1811-1818
31. van den Berg E, Geleijnse JM, Brink EJ et al (2012b) Sodium intake and blood pressure in renal transplant recipients. Nephrol Dial Transplant 27:3352-3359
32. van den Berg E, Pasch A, Westendorp WH et al (2014) Urinary sulfur metabolites associate with a favorable cardiovascular risk profile and survival benefit in renal transplant recipients. J Am Soc Nephrol 25:1303-1312
33. Vogelzang JL, van Stralen KJ, Noordzij M et al (2015) Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. Nephrol Dial Transplant 30:1028-1037
34. Yilmaz MI, Saglam M, Caglar K et al (2006) The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47:42-50
35. Yilmaz MI, Sonmez A, Saglam M et al (2010) FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 78:679-685
36. Zoccali C, Mallamaci F, Maas R et al (2002) Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62:339-345